Patients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive
standard of care chemotherapy followed by stereotactic body radiotherapy (SBRT) with
concurrent and adjuvant FAK inhibitor defactinib (experimental arm) or standard of care
chemotherapy followed by SBRT (control arm). Patients enrolled to the experimental arm will
be assessed for clinical outcomes such as progression free survival (PFS), local control,
distant control, and toxicity. The first 6 patients randomized to the experimental arm will
be considered the safety lead-in and will be assessed for dose-limiting toxicities (DLTs).
The 6 patients randomized to the control arm will be evaluated for correlatives but will not
be included in the analysis for primary and secondary endpoints.
Hypothesis: locally advanced pancreas cancer patients treated with SBRT and concurrent plus
adjuvant defactinib will have increased PFS compared to historical rates for patients
receiving SBRT alone.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
Research blood draw,
MR-guided stereotactic body radiation therapy
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.